On September 22 Roche ↗ reported topline phase 2 results for enicepatide ↗, a once-weekly injectable that switches on two gut-hormone receptors at once, and the numbers it chose to publish were large. Over 48 weeks in 447 adults who had type 2 diabetes plus overweight or obesity, the top 24-milligram dose lowered hemoglobin A1c by 2.65 percentage points from a starting average of 8.1 percent. Hemoglobin A1c is the standard blood-sugar marker that averages glucose over roughly three months. Ninety percent of people on that dose reached 6.5 percent or below, the threshold most guidelines use to call diabetes controlled, and 62 percent dropped under 5.7 percent, the range a person without diabetes sits in. Body weight fell 15.5 percent and was still falling at week 48, meaning the weight curve had not yet flattened.
The drug began life as CT-388, and Roche also lists it as RO7795068. It arrived through the company's 2023 purchase of Carmot Therapeutics. Enicepatide activates the GLP-1 receptor ↗ and the GIP receptor ↗, the same two gut-hormone switches that Eli Lilly's tirzepatide ↗ engages. Hitting both at once is the design bet behind the current generation of metabolic drugs: GLP-1 slows the stomach and blunts appetite, and adding GIP appears to let the body tolerate a higher effective dose before nausea forces people off. The discontinuation figures fit that story. Only 2.0 percent of people across the enicepatide arms stopped because of side effects, against 0.0 percent on placebo, so the drug held people on treatment about as well as a dummy injection did.
Read the release again and the missing column becomes the story. Roche reported the HbA1c drop and the weight loss as changes from each person's own baseline. It did not report what the placebo group did over the same 48 weeks. Placebo arms in metabolic trials are not flat. People enrolled in a diabetes study get more clinic contact, more glucose monitoring, and more diet coaching than they had before, and their numbers usually move. The honest measure of a drug is the gap between its arm and the placebo arm, not the distance each person traveled from their own start. That gap is exactly the figure the announcement withheld.
This is a press release, not a paper. It has cleared no peer review and no regulator, and the full dataset that would show the placebo-adjusted effect, the dose-by-dose safety detail, and how many people actually completed the study has not been published. The pattern is familiar for topline drops timed to investors. The company reports the flattering within-arm numbers first and lets the controlled comparison wait for a conference or a journal months later.
What enicepatide has not yet shown is whether it changes outcomes that patients feel. A 2.65-point HbA1c drop and 15 percent weight loss are surrogate markers, laboratory stand-ins for the heart attacks, strokes, and kidney failure that diabetes eventually causes. Roche says it will start a cardiovascular outcomes trial and a broader glycemic-control program in the first half of 2027, and two phase 3 weight-management studies, ENITH-1 and ENITH-2, are already running. Those are the trials that decide whether a drug prevents the events that matter, and they take years.
For now enicepatide joins a crowded field of dual GLP-1/GIP agonists chasing tirzepatide, which already has years of controlled data and regulatory approval behind it. As Healio ↗ noted in its coverage, the within-arm effect looks competitive with the class leaders. Whether it clears the same bar depends on numbers Roche has not released, against a comparator it did not name.